Formycon Files Aflibercept With US FDA

Klinge And Coherus Are US Partners For FYB203 Biosimilar Rival To Eylea

 
• By Dave Wallace

Formycon has announced the filing of its FYB203 aflibercept biosimilar rival to Eylea in the US. The product is set to be marketed by Coherus once approved.

US flag reflected in eye
Formycon has filed its second ophthalmic biosimilar in the US • Source: Shutterstock

More from Biosimilars

More from Products